James -
Thanks for your post.
I am aware of BIOX's product and budgeted for it heavily
in my 1998 P&L.
ANIK will get their first. Without proof, I want to suggest
they have about a 1 year head start. To my knowledge (I
don't have a medical/researcher background) there is no way
to make up this lead.
My thinking is that after ANIK launches Orthovisc, its
adhesion product is less than 12 months to marketplace.
(Assuming no pitfalls.)
Depending on what the "word" is about it at the time,
I may jump into ANIK. While maintaining my position
in BIOX.
This might sound like bulls*it, but I think with respect
to Adhesion products:there is nothing strong out there now ,
and knowning how fussy BIOX is, when they are ready, I
think, their product will be first rate, and consequently;
it will make the same kind of impact that Synvisc has.
Sometime ago, Eduardo advised me the adhesion marketPlace
is north of $1 bil.
But, and I am guessing, we are talking ANOTHER 2 years.
Regards,
John |
